

Patient Alert Card

APIGAT

Apixaban Tablets

Carry this card with you at all times

Show this card to your pharmacist, dentist and any other healthcare professionals that treat you.

Information for PATIENTS

- Take Apigat (apixaban) regularly as instructed. If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule.
- Do not stop taking Apigat (apixaban) without talking to your doctor, as you are at risk of suffering from a stroke or other complications.
- Apigat (apixaban) helps to thin your blood. However, this may increase your risk of bleeding.
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.
- If the bleeding does not stop on its own, **immediately seek medical attention.**
- If surgical or invasive procedures need to be performed, inform your doctor or dentist that you are taking Apigat (apixaban).

Folding line

For distribution by healthcare professionals to patients who have been prescribed with Apigat (apixaban).

Card open size: 50 x 88 mm folding size: 44 x 50 mm

Apixaban Card Singapore 12/01/2026

Printing Color: Pantone 2935 C Pantone 376C

Pantone Reflux Blue C, 021C, black

**I am under anticoagulation treatment
with Apigat (apixaban)
to prevent blood clots**

Please complete this section or ask your doctor to do it

Name: _____

Birth Date: _____

Indication: _____

Dose: _____ mg twice daily

Doctor's Name: _____

Doctor's telephone: _____

Information for HEALTHCARE PROFESSIONALS

- *To report an adverse event associated with the use of Apigat (apixaban), contact Natco Pharma Asia Pte. Ltd. via Telephone: +65 6493 7100 or Email: Apigat@natcopharma.sg*

- Apigat (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- Apigat (apixaban) may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Apigat (apixaban) does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery. Clotting tests such as prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) are not recommended.
- For more information, please refer to the approved Singapore package insert for Apigat.

Manufactured by:
Natco Pharma Limited
Kothur - 509 228
Rangareddy District
Telangana, India

XXXXXX



Marketed by:
Natco Pharma Asia Pte Ltd.
111, North Bridge Road,
23-05 Peninsula Plaza,
Singapore 179098

This document has been approved by HSA as of 09-01-2026.

Version 01

Folding line